16 completed, 13 recruiting, 12 unknown, 8 not yet recruiting. 59 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 59 | Completed 16, Recruiting 13, Unknown 12, Not yet recruiting 8, Terminated 5, Active not recruiting 3, Withdrawn 2 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia GT737 Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 36 | 2027-05-01 | 2026-09-11 |
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia Momelotinib, Azacitidine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 | 2026-03-19 | 2026-03-27 |
| Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML CAR-T - AML (Acute Myeloid Leukemia), CAR-T | Early Phase 1 | Withdrawn | First Affiliated Hospital of Guangxi Medical University | 2026-01-05 | 2026-08-26 | |
| UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C) - Acute Myeloid Leukemia, Pediatric AML | Early Phase 1 | Recruiting | Baylor College of Medicine | 36 | 2025-10-22 | 2026-08-24 |
| CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic - AML - Acute Myeloid Leukemia | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-09-30 | 2025-10-01 |
| Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia CD117 CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 50 | 2025-09-05 | 2025-08-27 |
| The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT Ex-vivo expanded allogeneic γδ T cells - AML (Acute Myelogenous Leukemia), AML | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-07-20 | 2025-08-17 |
| A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) Soursop tea - AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory | Early Phase 1 | Recruiting | Roger Strair | 20 | 2025-06-30 | 2026-08-18 |
| XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia Personalized neoantigen tumor vaccine, PD-1 inhibitor - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Shanghai Jiao Tong University School of Medicine | 60 | 2025-05-30 | 2025-05-20 |
| Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. RD-IIT-001, CD84-CART - Relapsed/Refractory Acute Myeloid Leukemia(AML) | Early Phase 1 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 18 | 2025-02-10 | 2025-01-22 |
| A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia CD33 CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 27 | 2025-01-10 | 2025-01-07 |
| Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia iNK cells - Acute Myeloid Leukemia (AML) | Early Phase 1 | Not yet recruiting | Guangzhou Ruixin Biotechnological Co., LTD | 10 | 2024-11-25 | 2024-11-22 |
| CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial Autologous CAR123 T lymphocytes - Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma | Early Phase 1 | Active not recruiting | Institute of Hematology and Blood Transfusion, Czech Republic | 18 | 2024-10-23 | 2026-09-14 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia CAR-T Cell Injection - Acute Myeloid Leukemia (AML), CAR-T | Early Phase 1 | Recruiting | Zhimin Zhai | 9 | 2024-09-01 | 2024-10-15 |
| Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia Hema-NeoTIL01 - Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 20 | 2024-09-01 | 2024-08-19 |
| Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia NK520 - Relapsed/Refractory Acute Myeloid Leukemia | Early Phase 1 | Terminated | Base Therapeutics (Shanghai) Co., Ltd. | 2 | 2024-07-01 | 2026-09-30 |
| Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia NK520 - Relapsed/Refractory Acute Myeloid Leukemia | Early Phase 1 | Terminated | Base Therapeutics (Shanghai) Co., Ltd. | 2 | 2024-07-01 | 2026-09-30 |
| Off-the-shelf CD123 CAR-NK for R/R AML JD123 injection - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Early Phase 1 | Recruiting | Peking University People's Hospital | 12 | 2023-12-30 | 2025-03-11 |
Showing 20 of 59. Sign in to see all of them.
Leukemia, Myeloid, Acute (54) · Myelodysplastic Syndromes (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Leukemia (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Lymphoma, Non-Hodgkin (5) · Primary Myelofibrosis (5) · Hematologic Neoplasms (4) · Hodgkin Disease (4) · Leukemia, Myelomonocytic, Chronic (4) · Multiple Myeloma (4) · Myeloproliferative Disorders (4) · Recurrence (3) · Burkitt Lymphoma (2)
Hemic and Lymphatic Diseases (59) · Neoplasms by Histologic Type (59) · Hematologic Diseases (58) · Neoplasms (58) · Leukemia (53) · Bone Marrow Diseases (16) · Immune System Diseases (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Disease Attributes (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Chronic Disease (10)
Cyclophosphamide (3) · Cytarabine (3) · Azacitidine (2) · Etoposide (2) · Idarubicin (2) · fludarabine (2) · pembrolizumab (2) · Atovaquone (1) · Biopsy (1) · Bortezomib (1) · Contrast Media (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Daunorubicin (1) · Exercise (1)
Zhejiang University (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (2) · Base Therapeutics (Shanghai) Co., Ltd. (2) · Baylor College of Medicine (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · iCell Gene Therapeutics (2) · Amgen (1) · Assiut University (1) · Carbiogene Therapeutics Co. Ltd. (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · First Affiliated Hospital of Guangxi Medical University (1) · First Affiliated Hospital of Zhejiang University (1)
China (30) · United States (22) · Germany (2) · Australia (1) · Czechia (1) · Denmark (1) · France (1)
Fang Liu, MD, PhD (2) · He Huang, MD (2) · Hongyu Zhang, MD, PhD (2) · Alexandra Stevens, MD (1) · Amanda Cashen, M.D. (1) · Bouthaina S Dabaja (1) · Candido E. Rivera, M.D. (1) · Christian B Gocke, MD, PhD (1) · Elizabeth A Griffiths (1) · Heng Mei, Doctor (1) · Heng Mei, MD (1) · Huo Tan, MD (1) · Jan Vydra, MD, PhD (1) · Jeffrey J. Raizer, MD (1) · Jeffrey Y Wong (1)
PMID 33439382, PMID 35468680, PMID 35973200, PMID 37093350, PMID 42040934
2017 (1), 2019 (1), P30CA015083 (1), P30CA033572 (1), P30CA043703 (1)